Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

NCT02304367 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor Induced Osteomalacia (TIO)
Epidermal Nevus Syndrome (ENS)

Interventions

BIOLOGICAL: Burosumab

Sponsor

Kyowa Kirin, Inc.